This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
19 Aug 2011

Boehringer Ingelheim & ProBioGen Sign Licensing Agreement for Antibody Technology

Boehringer Ingelheim will apply ProBioGen's technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of antibodies.

Pharmaceutical company Boehringer Ingelheim and biotechnology company ProBioGen AG have inked a non-exclusive licensing deal for ProBioGen's GlymaxX? technology.

 

Boehringer Ingelheim's Contract Manufacturing Business will apply the technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of antibodies.

 

The GlymaxX? technology for production of afucosylated proteins is universally applicable, simple and potent. As a unique feature, differentiating it from other approaches, the GlymaxX? technology can also be applied to already existing antibody producer cell lines without altering their productivity. The technology can easily be integrated into Boehringer Ingelheim's high expression CHO-based BI-HEX? system.

Related News